This article first appeared on GuruFocus.
Novo Nordisk (NVO, Financials), has agreed to pay up to 1.165 billion ($1.3 billion) for access to drug-delivery technology that could help the company develop obesity and diabetes treatments requiring fewer injections.
The Danish drugmaker signed a global licensing and collaboration agreement with Sweden’s Nanexa covering its PharmaShell technology for certain therapeutic peptide drugs.
The deal could cover as many as five development programs targeting obesity, type 2 diabetes and other cardiometabolic diseases.
The potentially important part for Novo is dosing frequency. The companies plan to explore different administration schedules, including monthly and quarterly injections.
Novo will lead global development and commercialization of products resulting from the collaboration.
Nanexa is eligible for 615 million in upfront payments and development and regulatory milestones. Total potential payments could eventually reach 1.165 billion if specified milestones are achieved.
Nanexa could also receive low single-digit royalties on future product sales.
The agreement adds another approach to Novo’s efforts to expand its cardiometabolic pipeline beyond its existing treatments. Longer-lasting formulations could become particularly important as drugmakers compete not only on weight loss and efficacy, but also on convenience for patients taking chronic therapies.
Novo shares closed Thursday at $38.62, up 1.2%.
The next catalyst will be which drug candidates Novo selects for the collaboration and whether the PharmaShell technology can advance longer-acting formulations into clinical development.